Booth G, Di Rosa A, Corcoran P, Hallisey C, Lucas A, Zarnegar R. Patient perspectives on the unwanted effects of multidisciplinary pain management programmes: a qualitative study. Clin Rehabil. 2024 May 15. doi: 10.1177/02692155241254250
DeWaters AL, Miller EL, Haidet P, Gonzalo JD. Systems-based practice: expert perspectives on the origin and evolution of an ambiguous competency. Acad Med. 2024 Apr 1;99(4):424-9. doi: 10.1097/ACM.0000000000005478
Gonzalo JD, Hamilton M, DeWaters AL, Munyon R, Miller E, Wolf H, Wolpaw DR, Thompson BM. Implementation and evaluation of an interprofessional health systems science professional development program. Acad Med. 2023 Jun 1;98(6):703-8. doi: 10.1097/ACM.0000000000005144
John NM, Wright SJ, Gavan SP, Vass CM. The role of information provision in economic evaluations of non-invasive prenatal testing: a systematic review. Eur J Health Econ. 2019 Nov;20(8):1123-31. doi: 10.1007/s10198-019-01082-x
Wilson MR, Bergman A, Chevrou-Severac H, Selby R, Smyth M, Kerrigan MC. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom. Eur J Health Econ. 2017 Mar;19(2):229-40. doi: 10.1007/s10198-017-0879-5.
Beard SM, von Scheele BG, Nuki G, Pearson IV. Cost-effectiveness of febuxostat in chronic gout. Eur J Health Econ. 2013 May;Advance online publication.
Greiner W, Lehmann K, Earnshaw S, Bug C, Sabatowski R. Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ. 2006 Dec 1;7(4):290-6.
Lehmann K, Radbruch L, Gockel HH, Neighbors D, Nuyts G. Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Duragesic) with controlled release morphine. Eur J Health Econ. 2002;3:111-9. doi: 10.1007/s10198-002-0097-6.
Ford HL, Gerry E, Tennant A, Whalley D, Haigh R, Johnson MH. Developing a disease-specific quality of life measure for people with multiple sclerosis. Clin Rehabil. 2001;15(3):247-58.